ArticleCureus2025
Methylmalonic Acidemia: A Review of Cases in Jordan.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background This study reviews methylmalonic acidemias (MMAs), one of the organic acid disorders, to create a foundation for future studies by establishing a comprehensive database. Moreover, it contributes to a deeper awareness of the clinical features and outcomes observed in individuals affected by this condition. Method This case series includes all MMA diagnoses at the metabolic unit of Queen Rania Al Abdullah Hospital for Children in Amman, Jordan, from 2010 to 2023. The review included sociodemographic features, clinical and laboratory results, familial history, and parental consanguinity. Results Our cohort comprised 14 individuals (seven males, seven females) with a mean age at presentation of 12.9 months. Positive family history was observed in 35.7% of cases, and parental consanguinity was observed in 85.7%. Mortality was reported in two patients (14.3%) during the study period at 3.8 and four years of age. Encephalopathy was documented in 57.1%. Failure to thrive and developmental delay were reported in six (42.9%) and five (35.7%) patients, respectively. Hypoglycemia emerged as the most prevalent laboratory finding, affecting 71.4% of cases. Additionally, hearing loss was noted in four patients (28.6%). Conclusions Due to the difficulties and delays in diagnosing these organic acidemia disorders, we highly recommend implementing newborn screening as a critical step for early intervention and guidance. For early intervention and guidance, health care professionals should possess a thorough understanding of the clinical manifestations of these disorders and proficiency in interpreting results from biochemical tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.